Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Cure dermatologiche avanzate per ridurre l'eruzione cutanea e la paronichia nel cancro polmonare non a piccole cellule (NSCLC) con mutazione del recettore del fattore di crescita epidermico (EGRF) trattato in prima linea con amivantamab più lazertinib (COCOON)

2 novembre 2026 aggiornato da: Janssen Research & Development, LLC

Uno studio randomizzato di fase 2, in aperto, che valuta l’impatto della gestione dermatologica avanzata rispetto a quella standard su eventi avversi dermatologici selezionati tra pazienti con NSCLC localmente avanzato o metastatico con mutazione di EGFR trattati in prima linea con amivantamab + lazertinib

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

305

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina, C1199
        • Hospital Italiano de Buenos Aires
      • CABA, Argentina, C1122
        • IADT Instituto Argentino de Diagnostico y Tratamiento
      • Capital Federal, Argentina, C1017
        • Centro Medico Austral
      • La Plata, Argentina, B1900AXI
        • Hospital Italiano de La Plata
      • Mar del Plata, Argentina, B7602
        • Hospital Privado de la Comunidad
      • Belo Horizonte, Brasile, 30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Belém, Brasile, 66.073-005
        • CTO Centro De Tratamento Oncologico LTDA
      • Curitiba, Brasile, 81520-060
        • Liga Paranaense de Combate ao Cancer
      • Jaú, Brasile, 17.210-080
        • Fundacao Doutor Amaral Carvalho
      • Porto Alegre, Brasile, 91350 200
        • Hospital Nossa Senhora da Conceicao S A
      • Salvador, Brasile, 40170 070
        • Nucleo de Oncologia da Bahia Oncoclinicas
      • Santa Cruz do Sul, Brasile, 96835-100
        • Hospital Ana Nery Santa Cruz do Sul
      • São Paulo, Brasile, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasile, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • Taubaté, Brasile, 12030-200
        • Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate
      • Vitória, Brasile, 29043-260
        • Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
      • Changzhou, Cina, 213004
        • Changzhou No 2 Peoples Hospital
      • Chengdoucun, Cina, 610041
        • West China Hospital
      • Chengdu, Cina, 610041
        • Sichuan Cancer Hospital
      • Guangzhou, Cina, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou, Cina, 310003
        • The First Affiliated Hospital Zhejiang University School of Medicine
      • Harbin, Cina, 150040
        • Harbin medical university cancer hospital
      • Huizhou, Cina, 516001
        • Huizhou Municipal Central Hospital
      • Nanjing, Cina, 210000
        • Zhongda Hospital Southeast University
      • Shanghai, Cina, 200032
        • Fudan University Shanghai Cancer Center
      • Xi'an, Cina, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Zhengzhou, Cina, 450008
        • Henan Cancer Hospital
      • Cheongju-si, Corea del Sud, 28644
        • Chungbuk National University Hospital
      • Incheon, Corea del Sud, 21565
        • Gachon University Gil Medical Center
      • Seoul, Corea del Sud, 03722
        • Severance Hospital Yonsei University Health System
      • Marseille, Francia, 13915
        • Hopital Nord
      • Nice, Francia, 06001
        • Hopital PASTEUR
      • Paris, Francia, 75005
        • Institut Curie
      • Aachen, Germania, 52074
        • Universitaetsklinikum der RWTH Aachen
      • Essen, Germania, 45136
        • Kliniken Essen-Mitte
      • Giessen, Germania, 35392
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Heidelberg, Germania, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Kassel, Germania, 34125
        • Klinikum Kassel GmbH
      • Kiel, Germania, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • George Town, Malaysia, 10450
        • Hospital Pulau Pinang
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Kuantan, Malaysia, 25100
        • Hospital Tengku Ampuan Afzan
      • Kuching, Malaysia, 93586
        • Hospital Umum Sarawak
      • A Coruña, Spagna, 15006
        • Hosp Univ A Coruna
      • Alicante, Spagna, 03010
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Spagna, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, Spagna, 08035
        • Hosp Univ Vall D Hebron
      • Jaén, Spagna, 23007
        • Hosp. Univ. de Jaen
      • Lugo, Spagna, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, Spagna, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Málaga, Spagna, 29010
        • Hosp Regional Univ de Malaga
      • Seville, Spagna, 41014
        • Hosp. Ntra. Sra. de Valme
    • Arizona
      • Chandler, Arizona, Stati Uniti, 85224
        • Ironwood Cancer and Research Center
    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope
      • Fullerton, California, Stati Uniti, 92835
        • Providence Fullerton
      • Glendale, California, Stati Uniti, 91204
        • Los Angeles Cancer Network
      • Huntington Beach, California, Stati Uniti, 92648
        • City of Hope Seacliff
      • Irvine, California, Stati Uniti, 92618
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Long Beach, California, Stati Uniti, 90813
        • City of Hope Long Beach Elm
      • Los Alamitos, California, Stati Uniti, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Stati Uniti, 90033
        • Keck Hospital of USC
      • Newport Beach, California, Stati Uniti, 92663
        • USC Norris Oncology Hematology Newport Beach
      • Oakland, California, Stati Uniti, 94611
        • Kaiser Permanente Oakland Medical Center
      • Roseville, California, Stati Uniti, 95661
        • Kaiser Permanente Roseville Medical Center
      • San Francisco, California, Stati Uniti, 94115
        • Kaiser Permanente San Francisco Medical Center
      • Santa Clara, California, Stati Uniti, 95051
        • Kaiser Permanente Santa Clara Medical Center
      • South Pasadena, California, Stati Uniti, 91030
        • City of Hope South Pasadena
      • Vallejo, California, Stati Uniti, 94589
        • Kaiser Permanente Northern California
      • Walnut Creek, California, Stati Uniti, 94596
        • Kaiser Permanente Walnut Creek Medical Center
    • Georgia
      • Athens, Georgia, Stati Uniti, 30607
        • University Cancer & Blood Center
    • Illinois
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Hope and Healing Care
    • Missouri
      • Springfield, Missouri, Stati Uniti, 65807
        • Oncology Hematology Associates
    • Nevada
      • Reno, Nevada, Stati Uniti, 89502
        • Renown Health Medical Oncology
    • New Jersey
      • Flemington, New Jersey, Stati Uniti, 08822
        • Hunterdon Hematology Oncology
    • New York
      • Westbury, New York, Stati Uniti, 11590
        • Clinical Research Alliance Inc
    • North Carolina
      • Wilson, North Carolina, Stati Uniti, 27893
        • Regional Medical Oncology Center
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Virginia Cancer Specialists
    • Washington
      • Renton, Washington, Stati Uniti, 98055
        • Valley Medical Center
    • Wisconsin
      • West Salem, Wisconsin, Stati Uniti, 54669
        • Gundersen Health System
      • Hsinchu, Taiwan, 30059
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City, Taiwan, 833
        • Chang Gung Memorial Hospital
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Taoyuan City, Taiwan, 333
        • Linkou Chang Gung Memorial Hospital
      • Adana, Turchia (Türkiye), 1060
        • Adana City Hospital
      • Ankara, Turchia (Türkiye), 06560
        • Gazi University Hospital
      • Ankara, Turchia (Türkiye), 06010
        • Gulhane Training and Research Hospital
      • Ankara, Turchia (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Istanbul, Turchia (Türkiye), 34147
        • Bakirkoy Training and Research Hospital
      • Istanbul, Turchia (Türkiye), 34295
        • I A U VM Medical Park Florya Hastanesi
      • Izmir, Turchia (Türkiye), 35100
        • Ege University Medical Faculty
      • Samsun, Turchia (Türkiye), 55420
        • Ondokuz Mayis University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
  • Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
  • A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
  • Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
  • Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care [SoC]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)

Exclusion Criteria:

  • History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
  • Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
  • Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
  • Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A: Enhanced Dermatologic Management

Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1).

Amivantamab will be administered.

Altri nomi:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Comparatore attivo: Arm B: Standard-of-Care Dermatologic Management

Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm.

Amivantamab will be administered.

Altri nomi:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Sperimentale: Sub-study: Cohort A: Ruxolitinib

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

Altri nomi:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Sperimentale: Sub-study: Cohort B: Tacrolimus

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

Altri nomi:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Tacrolimus will be used as topical application to the affected skin area.

Sperimentale: Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Amivantamab will be administered as SC injection.

Altri nomi:
  • JNJ-61186372

Zinc gluconate tablet will be administered.

Propranolol tablet will be administered.

Timolol will be used to the affected skin area.

Clobetasol shampoo will be used on the scalp.

Sperimentale: Amivantamab SC Expansion Cohort: Modified Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

Altri nomi:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Amivantamab will be administered as SC injection.

Altri nomi:
  • JNJ-61186372

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
Lasso di tempo: Up to 12 weeks after initiation of anticancer treatment

Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 12 weeks after initiation of anticancer treatment

Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 weeks after initiation of anticancer treatment
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 6 months after initiation of anticancer treatment

Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Grade >= 2 DAEI Per Participants
Lasso di tempo: Up to 12 months

Number of grade >= 2 DAEI per participants will be reported.

Up to 12 months
Time to First Occurrence of Grade >=2 DAEI
Lasso di tempo: Up to 12 months

Time to first occurrence of Grade >=2 DAEI will be reported.

Up to 12 months
Time to Resolution of Grade >= 2 DAEI
Lasso di tempo: Up to 12 months

Time to resolution of Grade >= 2 DAEI will be reported.

Up to 12 months
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 6 months after initiation of anticancer treatment

Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 12 months after initiation of anticancer treatment

Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 months after initiation of anticancer treatment
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months
Lasso di tempo: Baseline, up to Month 12

Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions.

Baseline, up to Month 12
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months
Lasso di tempo: Baseline, up to Month 12

Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale.

Baseline, up to Month 12
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months
Lasso di tempo: Baseline, up to Month 12

Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline, up to Month 12
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only)
Lasso di tempo: Baseline, up to Month 12

The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]).

Baseline, up to Month 12
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs
Lasso di tempo: Up to 12 months

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported.

Up to 12 months
Relative Dose Intensity (RDI) of Anticancer Treatment
Lasso di tempo: Up to 12 months

Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose.

Up to 12 months
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 12 months

Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
Lasso di tempo: Up to 12 months

Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Progression Free Survival (PFS)
Lasso di tempo: Up to 12 months

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first.

Up to 12 months
Overall Response Rate (ORR)
Lasso di tempo: Up to 12 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator.

Up to 12 months
Duration of Response (DoR)
Lasso di tempo: Up to 12 months

DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria.

Up to 12 months
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment
Lasso di tempo: Up to 12 weeks after initiation of anticancer treatment

Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention
Lasso di tempo: Up to 12 months

Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention
Lasso di tempo: Up to 12 months

Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event
Lasso di tempo: Up to 12 weeks

Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported.

Up to 12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 febbraio 2024

Completamento primario (Stimato)

31 maggio 2027

Completamento dello studio (Stimato)

30 giugno 2030

Date di iscrizione allo studio

Primo inviato

2 novembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

2 novembre 2023

Primo Inserito (Effettivo)

7 novembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 61186372NSC2007
  • 61186372NSC2007 (Altro identificatore: Janssen Research & Development, LLC)
  • 2023-505863-35-00 (Identificatore di registro: EUCT number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .